In This Section
Susan M. Galbraith, MBBChir, PhD

Susan M. Galbraith, MBBChir, PhD

AstraZeneca
Cambridge, United Kingdom

Class of 2024

For visionary contributions to the clinical development of several cancer medicines, including ipilimumab, the first immune checkpoint inhibitor; nivolumab, the first PD1 inhibitor in multiple indications; olaparib, the first PARP inhibitor; osimertinib for lung cancer; durvalumab for multiple cancers; tremelimumab for lung and hepatocellular cancers; savolitinib for lung cancer; acalabrutinib for chronic lymphocytic leukemia, and capivasertib for breast cancer.

*Full-length biography pending